Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. Show more
Location: 7171 Frederick-Banting, Building 2, Montreal, QC, H4S 1Z9, Canada | Website: https://www.reparerx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
67.34M
52 Wk Range
$0.89 - $4.29
Previous Close
$1.57
Open
$1.55
Volume
3,277,248
Day Range
$1.37 - $1.55
Enterprise Value
-63.24M
Cash
124.2M
Avg Qtr Burn
-29.38M
Insider Ownership
1.25%
Institutional Own.
69.46%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lunresertib (RP-6306) +/- Camonsertib (RP-3500) or Debio 0123 Details Ovarian cancer, Endometrial cancer | Phase 3 Initiation | |
Lunresertib (RP-6306) + gemcitabine Details Cancer, Advanced malignancies | Phase 2 Data readout | |
Camonsertib (RP-3500) +/- radiotherapy Details Solid tumor/s, Cancer | Phase 1/2 Update | |
RP-1664 Details Cancer, Neuroblastoma | Phase 1/2 Initiation | |
RP-1664 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
RP-3467 +/- olaparib Details Solid tumor/s, Cancer | Phase 1 Data readout | |
Lunresertib (RP-6306) + FOLFIRI Details Solid tumor/s, Cancer | Failed Discontinued | |
Lunresertib (RP-6306) + gemcitabine Details Solid tumor/s, Cancer | Failed Discontinued |